diarrhea-predominant irritable bowel syndrom. Irritable bowel syndrome with diarrhea
Conditions
Interventions
Intervention 1: Intervention group 1: high dose rifaximin, Rifaximin is a broad-spectrum antibiotic with minimal systemic absorption, which in our study is obtained from Actoverco. In this group, rifa
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Age above 18 years , History of colonoscopy or sigmoidoscopy with biopsy within the last 10 years Diagnosis of IBS based on ROME IV criteria Exclusion Criteria were
Exclusion criteria
Exclusion criteria: Liver disease ,, History of IBD (Inflammatory Bowel Disease), Previous gastrointestinal surgery ,Uncontrolled thyroid disease, Infection with immunodeficiency viruses such as Hepatitis B and C ,Use of anti-diarrheal, antispasmodic, narcotic, prokinetic drugs, warfarin, alosetron, lubiprostone, probiotics, or antibiotics within the past two weeks, Use of antidepressants within the last six weeks or recent dose changed kidney disease Diabetes History of IBD (Inflammatory Bowel Disease) Previous gastrointestinal surgery Uncontrolled thyroid disease Infection with immunodeficiency viruses such as Hepatitis B and C Use of anti-diarrheal Use of narcotic antispasmodic, Use of prokinetic drugs, Use of warfarin Use of alosetron Use of lubiprostone, Use of probiotics Use of antibiotics within the past two weeks Use of antidepressants within the last six weeks or recent dose changed
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Decrease 50 points in IBS-SSS score. Timepoint: baseline, after one month and after three month. Method of measurement: IBS-SSS questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAzin soltani
Esfahan University of Medical Sciences
Outcome results
None listed